What is the difference between an IND application in the US and a CTA in the EU for a first-in-human clinical trial?
An Investigational New Drug (IND) application is filed with the U.S. FDA to begin testing an investigational drug in people. A Clinical Trial Application (CTA) is filed — now exclusively through the EU's CTIS portal — to start the same kind of trial in the EU/EEA. Both rely on a similar core dossier, but differ sharply in review timeline and in whether a sponsor may proceed once the clock runs out, or must wait for an explicit "yes."
For a sponsor planning a first-in-human study, the choice usually isn't IND or CTA — it's how to sequence and resource both, often for the same molecule and sometimes for the same protocol. The two pathways share a regulatory ancestor (both trace back to the same ICH harmonization effort) but have evolved into genuinely different systems, with different clocks, different default outcomes, and different places where a regulatory operations team can lose weeks to an avoidable mismatch. This guide compares them side by side — what each application actually is, how their timelines and content requirements differ, what changed in the EU in 2025, and what a team running a global first-in-human program needs to plan for.
Table of Contents
- 1. What an IND and a CTA Each Are
- 2. Who Has to File, and When
- 3. IND vs. CTA, Side by Side
- 4. How the Review Timelines Actually Compare
- 5. What Goes Into Each Submission
- 6. Agency Correspondence and Oversight After Filing
- 7. Running Both at Once: A Global First-in-Human Strategy
- 8. Expedited and Special Pathway Programs Compared
- 9. What Changed — and What's Still Changing — Through 2026
- 10. Managing Both Submission Types in One System
- FAQ
1. What an IND and a CTA Each Are
The IND (United States)
An IND is a request, submitted to the FDA's Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER), for authorization to administer an investigational drug or biologic to human subjects. It's governed by 21 CFR Part 312[2], and it exists because the Federal Food, Drug, and Cosmetic Act otherwise prohibits shipping an unapproved drug across state lines for clinical use — the IND is the legal mechanism that exempts a sponsor from that prohibition for the purposes of a specific, FDA-reviewed trial. For a deeper walkthrough of what actually goes into the submission itself, see Kivo's dedicated guide to submitting an IND application.
An IND isn't a one-time filing. It's a living submission: the original application (Form FDA 1571, the investigator's brochure, the protocol, chemistry/manufacturing/controls (CMC) data, and pharmacology/toxicology data) opens it, and the sponsor keeps amending it — protocol amendments, information amendments, safety reports, and annual reports — for as long as the IND stays active across every subsequent trial of that drug.
Most sponsors don't arrive at the IND cold. A pre-IND meeting with FDA — informal, but commonly requested by sponsors developing a novel molecule or an unusual trial design — is where a sponsor can raise nonclinical package questions, proposed starting dose, and overall development strategy before committing to a submission date. It isn't required, and skipping it doesn't block a filing, but it's the most common way sponsors reduce the odds of a clinical hold once the 30-day clock described in Section 4 actually starts running.
The CTA (European Union / EEA)
A CTA is the application a sponsor files to run a clinical trial in one or more EU/EEA member states. Since the Clinical Trials Regulation (EU) No 536/2014 ("the CTR") became fully applicable, every new CTA in the EU/EEA is submitted through a single online portal — the Clinical Trials Information System (CTIS)[3] — rather than filed separately, country by country, the way trials were handled under the CTR's predecessor, the 2001 Clinical Trials Directive.
A single CTIS submission can cover multiple member states at once: the sponsor designates which countries it wants the trial to run in (the "Member States Concerned," or MSCs) and which one will coordinate the scientific review (the "Reporting Member State," or RMS). That one submission is then split into two parts for assessment — described in detail in Section 4 — rather than becoming twenty separate national applications. Kivo's own CTA guide for biopharma and medtech teams walks through that submission content in more depth.
2. Who Has to File, and When
In the United States, an IND is required before a sponsor may legally administer an investigational drug to a human subject anywhere in the country, with narrow exceptions (certain already-marketed drugs studied within their approved use, for instance). For a genuinely novel molecule, the IND is the gate: no IND, no dosing — whether the study is a Phase 1 first-in-human trial or a later-phase study of the same drug.
In the EU/EEA, the trigger is the same in substance — a sponsor needs an authorized CTA before enrolling the first participant in any of the member states named in that submission — but the mechanics differ in one important way covered in the next section: unlike the US's "the clock ran out, you may proceed" default, EU authorization has to be affirmatively granted before the trial can start in that country.
The pathway stays the same regardless of what kind of product is being studied — a small molecule, a biologic destined for an eventual Biologics License Application (BLA) rather than a New Drug Application (NDA), a cell or gene therapy, or a combination product — though the specific nonclinical and CMC content expected within Modules 2–5 (Section 5) scales with the product's complexity. A cell or gene therapy program, for instance, triggers additional FDA review considerations under its specialized programs and, on the EU side, often qualifies for PRIME's enhanced support (Section 8) precisely because advanced therapy medicinal products are exactly the kind of unmet-need product PRIME was built around. Pediatric development plans are a similar cross-cutting requirement in both regions — a Pediatric Study Plan in the US, a Paediatric Investigation Plan in the EU — that a sponsor needs to track alongside, not instead of, the core IND or CTA.
Both regimes also require parallel ethical review — Institutional Review Board (IRB) approval in the US, and ethics committee opinion in the EU — but the EU folds that ethics opinion into the same CTIS submission and review clock (Part I and Part II, below), while the US IND and IRB review run on separate, only loosely coordinated tracks.
3. IND vs. CTA, Side by Side
The table below compares the two pathways across the dimensions that matter most for planning a submission — not a feature-by-feature regulatory treatise, but the practical differences a regulatory operations team runs into first.
| Dimension | IND (United States) | CTA (EU/EEA, via CTIS) |
|---|---|---|
| Reviewing authority | FDA (CDER or CBER)[1] | One Reporting Member State's national competent authority for the shared scientific review, plus each Member State Concerned individually for national-specific items[3] |
| Legal basis | 21 CFR Part 312[2] | Regulation (EU) No 536/2014[4] |
| Submission system | FDA Electronic Submissions Gateway (eCTD) | CTIS (single portal, all EU/EEA member states)[3] |
| Countries covered by one filing | One (the US) — a separate filing is needed for every other country | As many EU/EEA member states as the sponsor names as Member States Concerned, in one submission |
| Default if the agency doesn't respond in time | Sponsor may proceed automatically 30 calendar days after FDA receives the IND, unless FDA places it on clinical hold[1] | No automatic default — the trial may not start in a given member state until that state issues an explicit authorization decision[5] |
| Ethics review | Separate track: Institutional Review Board (IRB) approval, coordinated with but not merged into the IND review clock | Folded into the same CTIS submission and assessment timeline (Part I / Part II, see Section 4) |
| Core technical dossier | Protocol, investigator's brochure, CMC data, pharmacology/toxicology data — broadly CTD-aligned | Equivalent CTD-aligned technical dossier (Part I), plus a national dossier per member state (Part II — informed consent, data protection, site suitability) |
| Ongoing safety reporting | IND safety reports to FDA — expedited (7- or 15-calendar-day) reports for certain serious, unexpected adverse events, plus annual reports | Suspected Unexpected Serious Adverse Reactions (SUSARs) reported to EudraVigilance, visible to all Member States Concerned |
| Amendments | Protocol amendments and information amendments filed to the existing IND | "Substantial modifications" filed through CTIS, assessed under a similar Part I / Part II split |
| Application fee | No FDA user fee for the IND itself (PDUFA user fees apply later, at the NDA/BLA stage) | Set independently by each Member State Concerned's own national fee schedule — amounts and fee-waiver rules vary by country |
4. How the Review Timelines Actually Compare
This is where the two systems diverge most for day-to-day planning purposes.
Figure 1: Time to Proceed, Absent Any Delay
The IND's clock has an automatic "proceed" default if FDA stays silent; the CTA's Part I assessment does not, and every named Member State Concerned still has to issue its own Part II authorization separately.
The IND's 30-day clock
Once FDA receives a complete IND, a 30-calendar-day clock starts. If FDA has significant concerns — about subject safety, trial design, or the adequacy of nonclinical data, for example — it can place the IND on full or partial clinical hold, which stops the sponsor from proceeding (or continuing) until the hold is resolved[1]. If the 30 days pass without a clinical hold, the sponsor may begin the trial without receiving any further communication from FDA — silence is effectively authorization. That "default to proceed" design is one of the most practically important features of the US system, and it's also the single biggest contrast with the EU.
The CTA's two-part assessment
A CTIS submission is assessed in two parts that run on related but distinct clocks[5]:
- Part I is the scientific and safety core — essentially the same substance as an IND's technical dossier — assessed once, jointly, by the Reporting Member State with input from every Member State Concerned. The regulation sets this assessment at up to 45 calendar days from validation, extendable by up to 31 additional days if the Reporting Member State sends a request for information (12 days for the sponsor to respond, 19 for the member states to complete their review), and by up to a further 50 days when the trial involves an advanced therapy medicinal product requiring additional expert consultation[5].
- Part II covers what's specific to each member state — informed consent requirements, data protection compliance, site and investigator suitability, and compensation arrangements — and is assessed independently, in parallel, by each Member State Concerned. The regulation sets no EU-wide day count for Part II the way it does for Part I; each Member State Concerned runs its own national timeline, and the Part I extension mechanisms above don't apply to it[5].
The practical consequence: a sponsor doesn't get one up-or-down answer. It gets a Part I decision shared across the whole submission, plus a separate Part II decision from each member state it named — and the trial can only start in a given state once that state has issued its own authorization. There is no US-style "the clock lapsed, so we may proceed" fallback anywhere in this process; every member state has to say yes.
Request-for-information clocks, expert-consultation requirements, and country-specific backlogs mean real-world CTA timelines often run well beyond the regulation's 45-day headline figure — a gap worth building into any program plan rather than assuming the textbook number.
5. What Goes Into Each Submission
Both pathways lean on the same international foundation — the ICH's Common Technical Document (CTD) structure for the scientific and manufacturing content — so a sponsor isn't building two unrelated dossiers from scratch. Where they diverge is Module 1, the regionally-specific administrative module that CTD deliberately leaves undefined at the international level precisely so each region can specify its own requirements.
For a US IND, Module 1 includes FDA-specific administrative forms (Form FDA 1571 and 1572), the general investigational plan, and the investigator's brochure in FDA's expected format. For an EU CTA submitted through CTIS, the equivalent administrative content follows the EU's own Module 1 (sometimes referenced alongside the Investigational Medicinal Product Dossier, or IMPD) and is submitted alongside the trial's protocol synopsis, informed consent materials, and the national-specific Part II content described above.
Two content differences are worth planning around specifically:
- Ethics committee opinion is submitted inside the CTIS filing as part of Part II, reviewed on the same timeline as the rest of the national assessment — whereas in the US, IRB review is a separate submission to a separate reviewing body, on its own timeline, that a sponsor has to coordinate with (not substitute for) the IND review.
- Informed consent and data protection documentation is country-specific in the EU by design — each Member State Concerned's Part II assessment exists specifically to check these against that country's own requirements, including GDPR compliance for clinical trial data — while a US IND's consent requirements are assessed once, nationally, under 21 CFR Part 50.
Mapped onto the ICH Common Technical Document's five modules, the shared versus region-specific split looks like this: Module 1 (administrative information and prescribing information) is fully region-specific in both systems; Modules 2 through 5 (overall summaries, quality/CMC data, nonclinical study reports, and clinical study reports) are written once, in a common format, and adapted only at the margins — a different regional cover letter or a locally-required summary, rather than different underlying data. That's the structural reason a shared nonclinical package and a shared protocol can genuinely serve both an IND and a CTA: the scientific substance lives in Modules 2–5, and those modules are the same CTD modules regardless of which region receives them.
Both regions expect the trial to be conducted to the same underlying standard of good clinical practice — ICH's E6 guideline, most recently revised as E6(R3)[6] — which is part of why the clinical and scientific content of a global first-in-human protocol can genuinely be shared across an IND and a CTA even though the regional wrapper around it can't. For the fuller ICH picture beyond E6 and the CTD, see Kivo's overview of ICH guidelines.
6. Agency Correspondence and Oversight After Filing
Filing the application is the start of an ongoing relationship with the regulator, not the end of one, and the two systems structure that relationship differently.
Under an IND, a sponsor can request formal meetings with FDA at defined points in development — Type B meetings around major milestones like the pre-IND or end-of-Phase-2 stage, Type C meetings for other substantive questions — each generating its own correspondence record that becomes part of the IND's history. Safety obligations run on their own clock: certain serious, unexpected adverse events trigger expedited IND safety reports to FDA within 7 or 15 calendar days depending on severity, on top of the annual report every active IND requires.
Under CTIS, correspondence is structured around the submission itself rather than around milestone meetings — requests for information from the Reporting Member State or a Member State Concerned are logged and answered inside the same system that holds the original application, visible to every Member State Concerned rather than routed through separate bilateral channels. Safety reporting follows the EU's own expedited-reporting framework: Suspected Unexpected Serious Adverse Reactions (SUSARs) are reported to EudraVigilance, where every Member State Concerned in the trial can see them, rather than reported to each national authority individually.
For a regulatory operations team running both, the practical difference is less about whether there's ongoing correspondence — there always is — and more about where it lives: IND correspondence accumulates against one FDA submission number across the life of the development program, while CTIS correspondence accumulates per-submission, visible across the member states named in that specific filing.
7. Running Both at Once: A Global First-in-Human Strategy
Most sponsors running a genuinely global first-in-human program aren't choosing between an IND and a CTA — they're sequencing or parallelizing both, usually alongside applications to other agencies (Health Canada, Japan's PMDA, Australia's TGA, and others) that follow their own variants of the same CTD-based structure. A few planning principles come up repeatedly:
- The clinical and scientific core should be written once, for all regions, not reworked per application. ICH harmonization exists specifically so the nonclinical package, the CMC data, and the protocol's scientific content can be shared across an IND, a CTA, and equivalent filings elsewhere — only the regional administrative wrapper (Module 1) needs to differ.
- Sequencing changes what "done" means in each region. Because the US defaults to proceed after 30 days absent a clinical hold, an IND can effectively clear in a month with no further agency action. A CTA cannot clear that way in any member state — every Member State Concerned has to issue its own authorization — so a sponsor sequencing US-then-EU (or EU-then-US) should plan around the EU leg needing an affirmative decision from each country it names, not just the passage of time.
- Choosing which EU member states to name as Reporting Member State and Member States Concerned is itself a strategic decision — it affects which national authority drives the shared Part I review and which countries' specific requirements (Part II) the sponsor has to satisfy in parallel, so it's worth deciding deliberately rather than defaulting to wherever a trial happens to have its first sites.
- Safety reporting obligations don't merge just because the underlying drug is the same. A serious adverse event occurring at a US site still has to be reported to FDA under the IND's own expedited-reporting rules, and one occurring at an EU site still has to be reported as a SUSAR to EudraVigilance — a global safety database doesn't substitute for meeting each region's own reporting mechanism and clock.
- A missed deadline in one region doesn't pause the other. Because the US and EU clocks are entirely independent, a request for information that stops the EU clock has no effect on an already-running IND, and vice versa — a regulatory operations team tracking both needs two live calendars, not one combined one, or it's easy to miss that a response is overdue in whichever region isn't top of mind that week.
Where Sponsors Actually Lose Time
A few specific, avoidable mistakes come up often enough in practice to call out directly:
- Treating the EU's Part II lead time as uniform across member states. Because each Member State Concerned runs its own national assessment, translation requirements, informed-consent localization, and site/investigator documentation can each add country-specific delay that a single "CTA timeline" estimate hides — budget per-country, not per-submission.
- Assuming the US's "silence means proceed" logic has any EU equivalent. There is no EU state in which a sponsor may start simply because a deadline passed without a response; treating an approaching EU deadline the way a team might watch an IND's 30-day clock — expecting to proceed by default — is the single most consequential mismatch between the two systems.
- Expecting an expedited-program designation to shorten the base application review. As Section 8 covers, Fast Track, Breakthrough Therapy, and PRIME change the intensity and cadence of agency interaction, not the IND's 30-day clock or the CTA's Part I/Part II assessment periods themselves.
- Underestimating translation and local-language requirements for EU informed consent materials. Because Part II assessment is explicitly national, informed consent documentation typically needs to be available in the local language of each Member State Concerned — a translation and local-review cycle that has no analog in a single-country US IND.
8. Expedited and Special Pathway Programs Compared
Both regions layer optional, faster-track programs on top of the base IND/CTA process — and the two sets of programs don't map onto each other one-to-one, which is a common source of confusion for a team assuming "we have Breakthrough Therapy, so we must qualify for the EU equivalent."
In the US, FDA offers four overlapping designations a sponsor can request for a drug addressing a serious condition: Fast Track (eligibility based on the condition and a plausible mechanism), Breakthrough Therapy (eligibility requires preliminary clinical evidence of substantial improvement over available therapies), Accelerated Approval (approval based on a surrogate or intermediate clinical endpoint, with a post-marketing confirmatory trial required), and Priority Review (a shortened FDA review clock for the eventual marketing application)[11]. These are requested alongside or after the IND — they don't change the IND filing itself, but they do change the cadence and depth of FDA interaction afterward, including more frequent formal meetings.
In the EU, the closest analog is the PRIME (PRIority MEdicines) scheme, which offers enhanced EMA support — earlier and more frequent scientific advice, a dedicated rapporteur — to medicines with the potential to address an unmet medical need, rather than a guaranteed faster CTA review[12]. The EU also has an accelerated assessment option at the marketing-authorization stage, structurally closer to the US's Priority Review than to Fast Track or Breakthrough Therapy. Critically, PRIME eligibility and designation happen on EMA's own timeline and criteria, entirely separate from a CTA's Part I/Part II assessment described in Section 4 — a sponsor can't fold a PRIME request into a CTIS submission and expect it to shorten the CTA review itself.
The practical takeaway: expedited-program eligibility has to be assessed and pursued separately in each region, on each region's own criteria, and neither program accelerates the other region's base application timeline.
9. What Changed — and What's Still Changing — Through 2026
Both systems have moved in the last two years, and a few of those changes directly affect how a sponsor should plan a submission today rather than by what used to be true.
Figure 2: Key Regulatory Milestones, 2024–2029
CTIS is no longer optional. The Clinical Trials Regulation included a three-year transition period during which sponsors could still file under the old Clinical Trials Directive system; that transition period ended January 31, 2025[10], so every new clinical trial application in the EU/EEA now goes through CTIS — there's no remaining path to file the old way.
eCTD format requirements are shifting underneath both regions, on different timetables. FDA has accepted new applications in eCTD v4.0 since September 2024, while ICH's own implementation guidance lists v4.0 as mandatory in Japan from April 2026 and in the US from 2029[9]. On the EU side, EMA began accepting optional eCTD v4.0 submissions for new centralized marketing authorization applications in December 2025, with use "strongly recommended" starting Q1 2027 and mandatory from Q1 2028[8]. None of these dates apply retroactively to an IND or CTA filed today, but a program expected to run multiple years should plan for at least one format transition along the way.
ICH's harmonization work underneath both pathways keeps moving too. ICH E2D(R1), which governs post-approval safety data management and reporting, reached Step 4 (the point at which ICH formally adopts a guideline for regional implementation) in 2026[7] — a reminder that the "shared scientific core" referenced throughout this guide isn't static; it's actively being revised, and a global regulatory strategy built today should expect to revisit its assumptions as each region implements the newest ICH revisions on its own schedule.
10. Managing Both Submission Types in One System
Kivo's Regulatory Information Management (RIM) module is built to support exactly this kind of multi-region submission work — INDs, CTAs, BLAs, NDAs, ANDAs, IDMPs, and CTIS submissions all managed inside the same system, on the same EDM Reference Model, rather than as separate tools per region. A few specifics relevant to an IND/CTA program specifically:
- Kivo's eCTD Viewer, included with the RIM module, supports eCTD formats accepted by the FDA (US), EMA (EU), Japan's PMDA, Health Canada, Switzerland's Swissmedic, Australia's TGA, Singapore's HSA, and South Korea's MFDS — so a sponsor reviewing a US and an EU submission side by side isn't switching between separate viewers per region.
- 450+ pre-formatted ICH templates cover FDA, Health Canada, and EU Module 1/IMPD formats, plus ICH M11 clinical protocol templates — the same harmonized protocol content referenced in Section 7 can be authored once and adapted per region from a shared template library rather than rebuilt from scratch for each filing.
- Correspondence and commitment tracking keeps FDA meeting records (Type B/C correspondence, IND safety report history) and EU national-authority and ethics-committee correspondence organized against their respective submissions in one system, with automated tracking as agency commitments and deadlines come due — relevant given Section 6's point that IND and CTIS correspondence structurally live in different places.
Kivo doesn't perform eCTD publishing itself — by design, to avoid marking up a third-party publishing tool or creating vendor lock-in — so submission-ready packages, with automatic change tracking, are handed off to whichever internal or external publishing group a sponsor already works with, and the submitted eCTDs remain viewable and linked back to their source documents in Kivo's DMS afterward.
Kivo's RIM module is built for the clinical-stage biotech teams running this kind of global first-in-human program for the first time, alongside the CROs and regulatory consultancies supporting them — see Kivo's Regulatory Information Management page, or request a demo for a closer look.
Frequently Asked Questions
What is the difference between an IND and a CTA?
An IND is filed with the FDA to begin testing an investigational drug in the US, under 21 CFR Part 312. A CTA is filed through the EU's CTIS portal to start a trial in one or more EU/EEA states, under the Clinical Trials Regulation. Both share a similar dossier but differ in timeline and whether explicit authorization is required.
How long does an IND review take compared to a CTA review?
An IND runs on a 30-calendar-day clock: absent a clinical hold, the sponsor may proceed once it lapses. A CTA has no such default — its Part I scientific assessment runs up to 45 days, and each Member State Concerned must separately authorize its own Part II before a trial can start there.
Can a sponsor file an IND and a CTA for the same trial at the same time?
Yes — many global first-in-human programs file both in parallel, or sequence them deliberately, using a shared clinical and scientific dossier (aligned to ICH's CTD structure) with region-specific administrative content built on top. Each filing still runs on its own clock and has to satisfy its own safety-reporting and correspondence requirements independently.
What are the EU equivalents of an FDA IND application?
The direct equivalent is the Clinical Trial Application (CTA), filed through CTIS under the Clinical Trials Regulation (EU No 536/2014). Unlike the IND's single FDA review, a CTA's Part I scientific assessment is coordinated by one Reporting Member State while each Member State Concerned separately reviews its own Part II national requirements.
Does the EU's Clinical Trials Regulation (CTR/CTIS) change the CTA process?
It already has — CTIS replaced the prior country-by-country system under the 2001 Clinical Trials Directive, and as of January 31, 2025, every new EU/EEA clinical trial application must go through CTIS; the transitional option to file under the old system has ended.
Sources
- U.S. Food and Drug Administration, "IND Application Procedures: Clinical Hold." https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-clinical-hold
- Electronic Code of Federal Regulations, 21 CFR Part 312 — Investigational New Drug Application. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312
- European Medicines Agency, "Clinical Trials Information System (CTIS)." https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation
- European Parliament and Council of the European Union, Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536
- European Medicines Agency, "Clinical Trial Information System (CTIS): Evaluation Timelines." https://www.ema.europa.eu/documents/other/clinical-trial-information-system-ctis-evaluation-timelines_en.pdf
- International Council for Harmonisation, ICH E6(R3) Good Clinical Practice. https://www.ich.org/page/efficacy-guidelines
- gmp-compliance.org, "ICH E2D(R1) Guideline on Safety Data Management Reaches Step 4." https://www.gmp-compliance.org/gmp-news/ich-e2dr1-guideline-on-safety-data-management-reaches-step-4
- International Council for Harmonisation / European Medicines Agency, eCTD v4.0 Implementation Timeline. https://esubmission.ema.europa.eu/gateway/eCTD4.0Timeline_ICH_v1.pdf
- U.S. Food and Drug Administration, "Electronic Common Technical Document (eCTD) v4.0." https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd-v40
- European Medicines Agency, "Clinical Trials: Transition to the New EU System — One Year Left." https://www.ema.europa.eu/en/news/clinical-trials-transition-new-eu-system-one-year-left
- U.S. Food and Drug Administration, "Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review." https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
- European Medicines Agency, "PRIME: Priority Medicines." https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines

